Updated longitudinal data on acute exacerbation of chronic hepatitis b in patients with breast cancer receiving anthracyclinebased adjuvant chemotherapy: Therapeutic vs. Pre-emptive use of Lamivudine

Japanese Journal of Clinical Oncology

Volumn 41, Issue 9, 2011, Pages 1059-1066

  Sohn, Byeong Seok ^a,b   Ahn, Jin Hee ^a   Jung, Kyung Hae ^a   Ahn, Sei Hyun ^a   Son, Byung Ho ^a   Gong, Gyungyub ^a   Kim, Sung Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Acute exacerbation; Breast cancer; Chronic hepatitis B; Lamivudine; Prophylaxis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; LAMIVUDINE; PACLITAXEL; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BREAST CANCER; DISEASE EXACERBATION; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PROPHYLAXIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS REACTIVATION;

ACUTE DISEASE; ADULT; AGED; ALANINE TRANSAMINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; LOGISTIC MODELS; LONGITUDINAL STUDIES; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION; TAXOIDS; TREATMENT OUTCOME;

EID: 80052480557     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr106     Document Type: Article

References (22)

1. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528-30.
2. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
3. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8 (Suppl. 1):107-9.
4. Yeo W, Ho WM, Hui P, Chan PKS, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004;88:209-15.
5. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553-61.
6. Yeo W, Zee B, Zhong S, Chan PKS, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-11.
7. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996;78:2210-5.
8. Yeo W, Chan PKS, Ho WM, Zee B, Lam KC, Lei KIK, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-34.
9. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008;47:844-53.
10. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-30.
11. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:925-9.
12. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
13. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 1999;81:69-74.
14. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:540-6.
15. Kim MK, Ahn JH, Kim SB, Im YS, Lee SI, Ahn SH, et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med 2007;22:237-43.
16. Ahn JH, Kim SB, Yun MR, Lee JS, Kang YK, Kim WK. Alternative therapy and abnormal liver function during adjuvant chemotherapy in breast cancer patients. J Korean Med Sci 2004;19:397-400.
17. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
18. Tsai S-H, Dai M-S, Yu J-C, Ho C-L, Chen Y-C, Wu Y-Y, et al. Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine. Support Care Cancer 2010:1-9 [Epub ahead of print October 7, 2010].
19. Lau GKK, Yiu HHY, Fong DYT, Cheng H-C, Au W-Y, Lai LSF, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9.
20. Yeo W, Lam KC, Zee B, Chan PSK, Mo FKF, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-6.
21. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376-84.
22. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760-7.